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Ductal carcinoma in situ (DCIS) of the breast constitutes about 10% of all diagnosed breast cancers and, despite surgical removal, it
may recur, either as DCIS or invasive breast cancer. Nuclear grade and growth pattern according to Andersen et al as well as surgical
margins are factors that have been used to predict local recurrence, but ideally a set of tumour-specific factors should be identified
and used as prognostic markers. Many cell cycle regulatory gene products have been shown to be involved in the formation of
tumours and are either oncogenes or suppressor genes and involved in key processes in the transformation. We therefore
characterised the cell cycle regulators cyclin E, cyclin D1, p27 and p16 in a material of DCIS cases arranged in a tissue microarray.
With a manual tissue arrayer, 52% of the initial 177 DCIS samples were successfully targeted allowing immunohistochemical analyses
of all four proteins in 92 cases of DCIS. As also observed in invasive breast cancer, there was a trend indicating that DCIS cases with
high cyclin D1 were cyclin E low and oestrogen receptor-positive, whereas cyclin E high DCIS cases were cyclin D1 low and
oestrogen receptor-negative. For the 64 patients that did not receive postoperative radiotherapy, there were 16 local recurrences
(eight DCIS and eight invasive breast cancer) during a mean follow-up time of 63 months. Cyclin E, p27 or p16 were not associated
with local recurrence, but interestingly cyclin D1 was significantly and inversely associated with local recurrence, both using univariate
and multivariate analyses. In summary, using a tissue array approach we have shown that cyclin D1, besides growth pattern, is a
prognostic marker for local recurrence in DCIS.
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In situ carcinoma of the breast has been a more frequent
observation since the introduction of mammography screening,
now accounting for up to 20% of all mammographically detected
breast malignancies, compared to a few percent in the prescreen-
ing era (Rosner et al, 1980; Ringberg et al, 1991; Ernster et al, 2002)
As with invasive breast cancer, noninvasive breast lesions appear
to be heterogenous in nature and the relationship between
preinvasive and invasive disease is not yet fully clarified. Data
from histopathological studies show that proliferative changes
often are found in association with invasive cancer and both
atypical ductal hyperplasia (ADH) and DCIS provide a signifi-
cantly increased risk of subsequent invasive carcinoma (Dupont
and Page, 1985; Eusebi et al, 1994) Treatment with mastectomy
(ME) is curative in 95–100% of all DCIS cases (Sunshine et al,
1985;Fentiman et al, 1986). Breast-conserving therapy (BCT)
followed by postoperative radiotherapy (RT) provides a prognosis
similar to ME (Ringberg et al, 2000), whereas patients having BCT
without RT have an increased frequency of ipsilateral breast
tumour recurrences (Ringberg et al, 2000).
Throughout the years, many proposals for a prognostically
valuable histological classification system for DCIS have been
introduced and the two most widely adopted are based on either
nuclear grade (ng) in combination with architectural pattern
(Holland et al, 1994) or the presence or abscence of comedotype
necrosis (Silverstein et al, 1995b). Classification systems based on
various differentiation aspects of DCIS seem to be clinically
relevant, as the nuclear grade is strongly associated with disease
recurrence (Ringberg et al, 2000; Boland et al, 2003). Unfortu-
nately, the interobserver reproducibility of the analyses is low
(Douglas-Jones et al, 2000; Wells et al, 2000) and there is still a
need for a more objective basis for the classification of DCIS.
Andersen et al (1988) have further stressed the aspect of growth
pattern in DCIS . Previous investigations, where the growth pattern
has been divided into diffuse (including diffuse or tumour-
formingþdiffuse) and nondiffuse (including microfocal or
tumour forming) have also shown that a diffuse growth pattern
is associated with a higher recurrence rate (Ringberg et al, 2000).
There is a limited amount of key events in the transformation
process, and deregulation of cell cycle regulators seems to be one
important and frequent finding in many cancer forms. In invasive
breast cancer, many cell cycle regulators are aberrantly expressed
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Invasive breast cancers overexpressing cyclin D1 are predomi-
nantly oestrogen receptor (OR)-positive, whereas cyclin E high
tumours in contrast are OR-negative and often p27 low as well as
p53- and pRb-inactivated (Nielsen et al, 1999; Loden et al, 2002). It
is obvious that certain genetic alterations are clustered in breast
cancer and it is likely that these changes also are found in
preinvasive forms of breast cancer such as DCIS.
In the present study, we wanted to determine the expression of
various cell cycle regulating proteins in a series of DCIS cases
arranged in a tissue microarray (TMA) and to delineate potential
clusters of aberrations in cyclin D1, cyclin E, p27 and p16 and their
associations to local recurrence. We further wanted to assess if
TMAs are suitable for studies of preinvasive lesions such as DCIS.
MATERIAL AND METHODS
Patient materials
The total material consists of 177 patients with DCIS treated with
BCT. The diagnoses were registered at the population-based
Regional Tumour Registry in Lund between 1 September 1987 and
31 December 1991. Treatment guidelines for the Southern Health
Care Region of Sweden recommended ME for DCIS lesions
exceeding one fourth of the breast size or when the size or
location in the breast precluded BCT with a good cosmetic
outcome. Patients with smaller DCIS lesions were recommended to
enter a randomised trial, studying the effect of RT after BCT. In
this material, 64 patients received no adjuvant radiotherapy. The
median follow-up time for the total material was 63 months and
any event of ipsilateral local recurrence, DCIS as well as invasive
cancer, was recorded. All tumours have earlier been reevaluated
regarding histopathological features and sets of clinicopathological
parameters and tumour biological factors have also been reported
(OR, PgR, c-erb-B-2, bcl-2, p53, DNA ploidy status and Ki-67)
(Ringberg et al, 2001). Ethical permission for the study was
obtained from the Lund ethical committee.
Tissue array and immunohistochemistry
Fresh slides from all blocks were reviewed for representative areas
with DCIS and tissue arrays were prepared as described earlier
(Kononen et al, 1998). In brief, two 0.6mm punches were taken
from the selected areas in each donor block and mounted in a
recipient block containing approximately 200 biopsies. When
neither of the two biopsies included DCIS, a new set of two
biopsies were taken and mounted in a second array. For
immunohistochemistry, 6mm sections of the paraffin-embedded
tissue arrays were dried, deparaffinised, rehydrated and micro-
wave-treated for 10min in a citrate buffer (pH of 6.0) or EDTA
buffer (pH of 8.0) for cyclin E before being processed in an
automatic immunohistochemistry staining machine according to
standard procedures (Ventana 320–202, Ventana inc., Tucson, AZ,
USA or using Techmate 500, Dako, Copenhagen, Denmark). The
following antibodies were used: Cyclin D1 (1:1000 M1755, Dako,
Denmark), Ki-67, (1:200, M0722, DAKO, Denmark), cyclin E
(1:100 HE12, Santa Cruz, CA, USA), p16 (1:200, BD PharMingen,
San Jose, CA, USA), p27
Kip 1 antibody (1:200, DAKO, Denmark).
Antibody binding was visualised using diaminobenzidine as the
chromagen and slides were counterstained with haematoxylin.
When evaluating the expression of cell cycle regulators in the
DCIS arrays, the fraction of positively stained nuclei (NF), as well
as the nuclear staining intensity (NI), were determined. For p16,
there was no obvious variation in the nuclear intensities and NI
was therefore not evaluated for p16. Due to the occasional presence
of distinct cytoplasmatic staining for p16, p27 and cyclin D1, the
cytoplasmic intensity (CI) was also assessed for these proteins.
Both nuclear and cytoplasmic intensity were evaluated with a
semiquantitative scoring system (0–3) representing, 0¼none,
1¼weak, 2¼moderate and 3¼strong, staining.
Statistical methods
Spearman’s correlation test was used for the comparison of the
different parameters, whereas Kaplan–Meier and log-rank tests
were used for the ipsilateral local recurrence analyses. Multivariate
analyses were performed by a Cox-regression model. All calcula-
tions were performed with SPSS 11.0 (SPSS inc., Chicago, IL, USA).
RESULTS
Tissue array construction
In the present study, we wanted to test the applicability of TMAs
for targeting DCIS lesions. In 92 cases (52%) out of the initial 177,
we obtained relevant tissue cores with acceptable immunohisto-
chemistry for all four cell cycle regulators as exemplified in
Figure 1A. The majority of acceptable cores were targeted in the
first array. This was probably due to the fact that all blocks already
had undergone extensive sectioning and, consequently, the
remaining amount of representative DCIS lesions had decreased
to a minimum, especially in cases with small original lesions . As
expected, the precision rate depended on the size of the involved
ducts per se as well as on the total extent of the lesion.
Histopathological characteristics
In all, 11 of the 92 DCIS cases (11.9%) were ng 1, 37 (40.2%) ng 2
and 44 (47.8%) were ng 3. A similar distribution of the ng was seen
in the remaining, unsuccessfully biopsied, DCIS, suggesting that
the 92 cases were representative for a general DCIS population
without any obvious selection biases (data not shown). As reported
earlier, the growth pattern of DCIS might be an important
prognostic factor for ipsilateral local recurrence (Ringberg et al,
2000) and when classified according to Andersen et al, the growth
pattern of the DCIS cases were: 16 cases microfocal (focusp5mm,
no stromal reaction), 33 tumour-forming (macroscopic le-
sion45mm with stromal reaction), 37 diffuse (þ/  macrosco-
pically identifiable lesion, microscopically confluent þ/  stromal
reaction) and six tumour-forming and diffuse growth pattern.
In line with earlier studies, the growth pattern was divided into
diffuse (diffuse or diffuse and tumour forming) and nondiffuse
(tumour forming and/or microfocal) for further statistical
analyses. Thus, 43 cases (46.7%) had a diffuse and 49 (53.3%) a
nondiffuse growth pattern.
Immunohistochemical detection of p16, p27, cyclin D1 and
cyclin E
In an attempt to define the existence of G1/S aberrations and
possible clusters in DCIS, we analysed the protein content of
several cell cycle regulatory proteins. Examples of cyclin D1, cyclin
E, p16 and p27 immunohistochemical stainings are shown in
Figure 1B–E and the fractions of positive cells are illustrated in
Figure 2. Focus was set on the fraction of positive cells, but similar
results were obtained using staining intensities (data not shown).
In short, p16 seemed to be present in various fractions in the DCIS
cases and a mean value was used to split the DCIS cases in two
almost equally sized groups. Using a similar approach for cyclin E,
approximately 25% of the DCIS cases had high cyclin E protein
expression, which also corresponded to the separately clustered
tumours as denoted from the distribution illustrated in Figure 2.
The majority of DCIS cases were positive for p27 and tumours
were divided into three groups based on the distribution of p27
positivity (illustrated in Figure 2) producing a large group of
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downregulation of p27. Cyclin D1 varied substantially between
DCIS cases with an apparently bipolar distribution as illustrated in
Figure 2, and by using the mean (37%) as cutoff, two equally sized
groups were formed representative for low and high cyclin D1.
Similar results were obtained when the median value (40%) for
cyclin D1 was used as cutoff.
Proliferation
Cell cycle aberrations will presumably increase the proliferation in
tumours and we therefore characterised the proliferation in the
DCIS material using Ki-67 as a marker. Proliferation was positively
correlated to nuclear grade (P¼0.047) and among the cell-cycle-
related proteins only cyclin E correlated (positively) to prolifera-
tion (P¼0.046).
Associations between cell cycle regulatory proteins
Like others, we have earlier observed striking associations between
various aberrations in cell cycle regulatory proteins in invasive
breast carcinomas (Nielsen et al, 1999). In this material of DCIS,
we therefore wanted to clarify any potential links between the
fractions of positive cells of the analysed cell cycle regulatory
proteins as well as examine their distribution and relation in
scatter plots in order to reveal potential patterns formed when
combining the cell cycle analyses. The associations between the cell
cycle regulatory proteins are presented in Table 1. The fraction of
p16-positive cells was associated with both p27 and cyclin D1 in
the DCIS material. The cdk-inhibitor p27 was further strongly
associated with cyclin D1 as reported earlier (Oh et al, 2001).
Interestingly, when the fractions of cyclin D1- and cyclin E-
positive cells were plotted in a scatter plot, a specific pattern was
formed as illustrated in Figure 3A. As also shown in Figure 3B, this
pattern is similar to previous data obtained from Western blot
analyses of invasive breast carcinomas (Nielsen et al, 1997),
suggesting that the relation between aberrations in these two cell
cycle regulatory proteins is comparable in DCIS and invasive
carcinomas. The OR-content is also illustrated in Figure 3A and,
noticeably, DCIS with higher cyclin D1 content were more often
OR-positive, whereas tumours with high cyclin E and low cyclin D1
in general were OR-negative. This association was nevertheless not
significant, probably due to the low numbers of cyclin E and D1
high DCIS.
Cell cycle aberrations in relation to clinicopathological
parameters and local recurrence
Local recurrence is a rare event after postoperative radiotherapy.
In this material, 28 patients (30%) received postoperative
radiation, while 64 patients (70%) did not. The overall recurrence
rate in the material was 17 cases (nine DCIS and eight invasive
carcinoma) and the vast majority occurred in the nonirradiated
group, n¼16. Only one local recurrence (DCIS) was seen in the
group that received adjuvant radiotherapy. Thus, when associating
ipsilateral local recurrence with other parameters, only the 64 cases
that did not receive adjuvant radiotherapy were included. In this
group, 30 cases had a diffuse and 34 cases a nondiffuse growth
pattern. In total, six cases (9 %) were nuclear grade 1, 26 cases
(41%) ng 2 and 32 cases (50%) ng 3. Only ipsilateral local
recurrences were considered in this study and, due to the relatively
small number of events, all recurrences (DCIS and invasive cancer)
were reported together.
All data concerning potential associations between cell cycle
aberrations and clinicopathological parameters are summarised in
Table 1. There was no association between the analysed cell cycle
regulatory proteins and growth pattern. Regarding ipsilateral local
recurrence, there was no association for the cell cycle regulators,
cyclin E, p16 and p27 (data not shown). Interestingly though,
cyclin D1 was strongly and inversely associated with ipsilateral
local recurrence as illustrated in Figure 4A. This was true for the
nuclear fraction (P¼0.02) as well as for the cytoplasmic intensity
(P¼0.02), but not for the nuclear intensity (P¼0.35). As shown in
Table 2, the time to the first recurrence was significantly prolonged
for cyclin D1 high cases. There were also fewer recurrences (six out
of 33 cases¼18%) in the cyclin D1 high group, compared to the
cyclin D1 low group (10 out of 31 cases¼32%), although this
difference was not statistically significant.
Of the diffusely growing DCIS cases, 12 out of 30 (40%) had
ipsilateral local recurrence compared to 4 out of 34 cases (12%)
Figure 1 Examples of immunohistochemical staining of the cell cycle
regulatory proteins in different DCIS tumours: (A)c y c l i nD 1l o w ;( B)c y c l i n
D1 high. (Note that the intensity of the cytoplasmic staining only differs
slightly between (A)a n d( B), in contrast to the nuclear staining.); (C)c y c l i nE
low; (D) cyclin E high; (E) p16 low; (F) p16 high; (G) p27 low; (H) p27 high.
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grade was also associated to a prolonged ipsilateral recurrence-free
interval (P¼0.04). There were no local recurrences for the six six
cases with nuclear grade 1, whereas four out of 26 (15%) with ng 2
and 12 out of 32 (37%) with ng 3 had local recurrences. The
presence or absence of comedo-type necrosis was not significantly
associated to local recurrence in the subset of 64 DCIS with
available data (P¼0.29). Margin width and tumour size were only
assessed in a small subset of the included DCIS cases and therefore
not further evaluated. An inclusion criterion for the study was
nevertheless that the DCIS lesion should be limited and the tumour
sizes of the DCIS cases in the study were presumably smaller than
an unselected DCIS cohort.
In multivariate analyses, including nuclear grade, OR receptor
status, growth pattern and cyclin D1, only growth pattern and
cyclin D1 were significantly associated with local recurrence
(Table 3). Surprisingly, in this model, both nuclear grade and OR
status were not significantly associated with local recurrence. Since
both cyclin D1 and growth pattern seemed to give independent
prognostic information, we also constructed a combined variable
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Figure 2 Distribution of the percentage positive cells for the analysed cell cycle regulators in 92 DCIS cases analysed by immunohistochemistry. The
cutoffs used in the analyses are indicated in the figure.
Table 1 Correlation analyses of cell cycle regulators and clinicopathological parameters in 92 cases of DCIS
Cyclin D1 Cyclin E p16 p27
Cyclin D1 — 0.257/0.119 0.0001/0.382
*** 0.0001/0.373
***
Cyclin E — — 0.157/0.149 0.769/0.031
p16 — — — 0.039/0.215
*
Ki-67 0.079/0.206 0.046/0.233
* 0.545/0.071 0.451/ 0.089
Age 0.486/0.074 0.592/0.057 0.784/0.029 0.048/ 0.207
*
OR+/  0.114/0.203 0.312/ 0.131 0.983/ 0.013 0.381/0.113
PR+/  0.171/0.147 0.098/ 0.177 0.315/ 0.108 0.8860/0.016
Nuclear grade 0.882/0.024 0.497/0.072 0.790/ 0.028 0.886/0.016
Growth pattern 0.555/0.062 0.508/0.070 0.122/0.162 0.748/0.034
(P-value/r-value).
*Po0.05,
***Po0.001. Progesteron receptor (PR).
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As illustrated in Figure 4C, this analysis produced a highly
significant difference in ipsilateral local recurrence-free interval
(po0.001). DCIS cases with low cyclin D1 in combination with a
diffuse growth pattern had the shortest ipsilateral local recurrence-
free survival and also the highest local recurrence rate with eight
out of 15 cases (53%). The figure further illustrates that for the
cases with a nondiffuse growth pattern, cyclin D1 protein
expression only seemed to have a marginal effect on the ipsilateral
local recurrence-free interval (P¼0.83) as well as the local
recurrence rate, with two out of 18 recurrences (11%) for cyclin
D1 high and 2/16 (12%) for cyclin D1 low cases. For the cases with
a diffuse growth pattern in combination with high cyclin D1, the
local recurrence rate was four out of 16 cases (26.6%), but the
ipsilateral local recurrence-free interval was significantly longer
than for the cyclin D1 low cases (P¼0.0007).
In a similar way, a combined cyclin D1 and nuclear grade
variable, produced a significant difference in the ipsilateral local
recurrence-free interval (P¼0.048).
DISCUSSION
In this study, we have observed a strong relationship between high
cyclin D1 expression in DCIS lesions and a prolonged ipsilateral
local recurrence-free interval, independently of the established and
prognostic important clinicopathological parameter nuclear grade
as well as the potentially valid prognostic factor growth pattern
(Ringberg et al, 2000). Both the fractions of positive nuclei and the
cytoplasmic intensity of cyclin D1 were significantly and inversely
associated with ipsilateral local recurrence, strengthening this
hypothesis. In order to increase the statistical power of the study,
all ipsilateral local recurrences (DCIS and invasive cancer) were
reported together. However, when local recurrences were split into
DCIS and invasive breast cancer, similar Kaplan–Meier curves for
the separate entities regarding cyclin D1 were produced (data not
shown), but with less statistical significance (P¼0.034 for DCIS
and P¼0.28 for invasive breast cancer). Larger studies are needed
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Figure 4 Kaplan–Meier plots of ipsilateral local recurrence (DCIS and
invasive breast cancer) in the material of 64 DCIS divided according to (A)
cyclin D1 protein content, (B) growth pattern according to Andersen et al
(1988) and (C) a combination of cyclin D1 and growth pattern.
Table 2 Fraction of disease recurrence and time to recurrence in cyclin D1 high and low DCIS (n¼64) cases.
Time to recurrence
Disease recurrence (%) All patients Patients with recurrence
Cyclin D1 low 32.3 4.27 years (P¼0.001) 2.29 years (P¼0.0002)
Cyclin D1 high 18.2 5.18 years 5.04 years
The significance values using nonparametric Mann–Whitney tests, for cyclin D1 low and high DCIS cases regarding time to recurrence, are indicated.
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D1 in DCIS and type of local recurrence.
Cyclin D1 is an important cell cycle regulating protein
functioning as a regulatory subunit for two cyclin-dependent
kinases, cdk 4 and cdk 6. The activated cyclin D1–cdk4/6
complexes initiate phosphorylation of pRb starting the cascade
of events that lead to DNA replication and subsequent cell division
(Sherr, 1996). Independently of its cdk-activating function, cyclin
D1 also interacts directly with the OR, thus enhancing the
transcription of OR-responsive elements (Zwijsen et al, 1997;
Lamb et al, 2000). The exact mechanisms for the transactivational
properties of cyclin D1, as well as the phenotypic consequences,
still have to be elucidated. This may, nevertheless, be an important
mechanism behind oestrogen-independent oncogenesis and for
tamoxifen resistance in OR-positive breast cancers. Another
interesting function for cyclin D1 is the apoptosis-stimulating
properties that have been observed in vitro (Han et al, 1996; Pardo
et al, 1996; Zhou et al, 2001; Katayama et al, 2003). In cyclin D1-
overexpressing cell lines, an increased incidence of apoptosis
following ionising radiation has been reported (Pardo et al, 1996;
Zhou et al, 2000). Turner et al (2000) also provide in vivo evidence
for a better response to RT in early-stage invasive breast cancer
with high cyclin D1 levels. Further studies are nevertheless needed
to clarify the role for cyclin D1 regarding an apoptotic phenotype
in DCIS.
Overexpression of cyclin D1 is observed in a fraction of cases
with DCIS and invasive breast cancer, and when studying
precancerous forms of breast cancer the breakpoint for increased
cyclin D1 expression has been observed between ADH and DCIS
(Alle et al, 1998; Gillett et al, 1998). This suggests that cyclin D1 is
involved in the early phase of the transformation process as also
supported by findings from transgenic mice overexpressing cyclin
D1 (Sutherland and Musgrove, 2002). Cyclin D1 is also essential for
the formation of functional breast tissue and cyclin D1 knockout
mice show defects in the formation of breast lobules during
pregnancy (Fantl et al, 1999). The results showing similar
patterns of cyclin D1 and cyclin E expression in DCIS and invasive
breast cancer (Figure 3A, B) also support that DCIS is rather
similar to invasive breast cancer, and that the majority of genetic
aberrations in tumour progression occur at or before the stage
of DCIS.
Most studies delineating the prognostic importance for cyclin
D1 overexpression in breast cancer have been performed using
invasive tumours and the results are diverging: some studies
indicate that cyclin D1 overexpression is associated with a negative
clinical outcome (Ohta et al, 1997; Kenny et al, 1999), some show
no prognostic significance (Michalides et al, 1996; van Diest et al,
1997), while others report a better prognosis for cyclin D1 high
tumours (Gillett et al, 1996; Hwang et al, 2003). One explanation
for the discrepancy could be that the fraction of patients treated
with antioestrogens varied between different studies and recent
experimental findings (Bindels et al, 2002; Hui et al, 2002) suggest
that cyclin D1 overexpression could induce resistance to
antioestrogen treatment. Data from our laboratory on patients
with invasive breast cancer, randomised to either tamoxifen or no
adjuvant therapy after surgery, also support the theory that cyclin
D1 overexpression is associated with an impaired prognosis in
antioestrogen-treated patients, but in contrast associated with a
more favourable outcome in untreated patients (to be published).
The observation that cyclin D1 overexpression is associated with a
prolonged ipsilateral local recurrence-free interval in cases with
DCIS is therefore in line with the above-described findings. The
DCIS patients in this study did not receive antioestrogen treatment
after surgery.
A second objective of this study was to evaluate whether DCIS
lesions are suitable for the construction of TMAs using a manual
tissue array approach. Compared to invasive cancer, premalignant
lesions of the breast are much more difficult to target than invasive
cancer, due to the often smaller size of the lesions and more
scattered appearances. Thus, the target rate of the DCIS lesions was
accordingly rather low and only 52% of the DCIS cases were
successfully arrayed. The paraffin blocks used for this study had
also been extensively sectioned earlier and the target rate would
probably increase if new paraffin blocks were used. Furthermore,
the precision in targeting specific areas of a small tumour would
most likely be improved if a video-equipped robotised tissue array
system could be used, simultaneously visualising the donor block
and the haematoxylin-stained section. Future studies will reveal
the target efficiency for modern tissue arrayers.
In summary, we have demonstrated that aberrations in G1/S-
regulatory proteins are present in DCIS and that they seem to be
rather similar to the aberrations observed in invasive breast
cancer. Among the analysed G1/S-regulatory proteins in DCIS,
cyclin D1 was inversely associated to ipsilateral local recurrence.
Our data clearly motivate further studies of cyclin D1 in DCIS in
order to validate the importance of this highly relevant tumour
biological parameter as a potential prognostic marker. As also
shown, TMAs can be used for studies of DCIS, enabling high
throughput analyses of preinvasive lesions, but with a rather low
targeting rate using a manual tissue arrayer.
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